

HIV & Respi **DART** 2022


LOS CABOS, MEXICO • 4-8 DECEMBER 2022

PROGRAM BOOKLET

Global Antiviral Journal

ISSN (Online): 1556-9055

FLOOR PLAN



Disclaimer: This conference aims to offer participants the opportunity to share information. The Organizing Secretariat of this conference, Informed Horizons Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this conference. Informed Horizons Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the conference.

TABLE OF CONTENTS

Meeting Objectives	5
Committees	6
Accreditation Statement	8
General Information	10
Scholarship Recipients	11
Program	12
Organizing Committee & Invited Speakers	22
Disclosure Statement	45
Acknowledgements	49

Webcasts and presentations will be posted on www.informedhorizonseducation.com shortly after the meeting.



Disclaimer: This conference aims to offer participants the opportunity to share information. The Organizing Secretariat of this conference, Informed Horizons Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this conference. Informed Horizons Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the conference.

WELCOME & INTRODUCTION



Raymond F. Schinazi
PhD, DSc, FAASLD

Program Chair 2022

Dear Colleagues,

The focus of **HIV & Respi DART 2022** is to assemble basic scientists, clinicians, medical professionals, and nurses together to advance our knowledge of the ongoing drug development process in the treatment and cure of HIV and SARS-CoV-2. After we held the 2020 conferences virtually due to the pandemic, we are pleased we have returned to an in-person format at the Hilton in Cabos San Lucas Mexico from December 4-8, 2022.

The DART series conferences highlight emerging challenges facing today's global community. Antiretroviral drug development against HIV has seen many successes over the past three decades. However, many barriers still remain unresolved. This year, we plan to address advancements in cure strategies, antiretroviral therapy and long-acting formulations. At the same time, the continued difficulties around the SARS-CoV-2 warrants an up-to-date, high-quality and multi-faceted platform where the latest developments and cutting-edge discoveries can be shared, discussed and analyzed.


HIV & Respi DART 2022 will focus on topics such as advances in epidemiology, diagnostics, therapeutics, vaccinology, immunity and inflammation, virus/host interactions, enzymology, and new study models in development. Emphasis is placed on sharing the latest clinical data for several small molecules advancing through human trials. Novel drug targets and mechanisms of action will also be heavily explored. Through participation in this back-to-back conference, delegates will be able to attend invited lectures by world-renowned leaders, participate in our poster receptions, and take advantage of key networking opportunities with peers and key opinion leaders.


Finally, this year we have the pleasure to honor Dr. James W. Curran and Dr. Christian Bréchet with distinguished lecture awards in recognition of their important contributions to the field of HIV and virology research and advocacy over the past several decades.

The in-person format of HIV & Respi DART 2022 will provide a highly invigorating and accessible platform for the global scientific community to engage with their peers and learn about the latest advancements in this arena. We look forward to seeing you this year!

Program co-chair on behalf of the Organizing Committees,

Raymond F. Schinazi, PhD, Hon DSc , FAASLD
Emory University, USA





MEETING OBJECTIVES

The scientific & learning objectives of HIV DART 2022 are:

- Novel approaches to suppress and eliminate HIV reservoirs
- Advances in antiretroviral therapy, long-acting formulations and injectable drugs for HIV
- HIV cure strategies
- HIV in the aging population
- Novel vaccines and immunological therapies in development
- Treatment as prevention and PrEP
- HIV co-infections with HCV, HBV and/or SARS-CoV-2
- Therapeutics and vaccine development for emerging viruses such as zika virus, dengue virus, chikungunya virus and yellow fever virus

The scientific & learning objectives of Respi DART 2022 are:

- Epidemiology, screening, and diagnosis of respiratory viruses with a special focus on the SARS-CoV-2 pandemic
- Drug discovery and development
- Pre-clinical and clinical evaluation of novel therapeutics in development against respiratory viruses such as SARS-CoV-2, influenza virus, RSV, parainfluenza virus, and metapneumovirus
- Long COVID-19
- Respiratory virus enzymology, host-virus interactions and virus replication
- Immunology and vaccine development
- Impact of SARS-CoV-2 variant emergence on therapeutics, vaccines and epidemiology
- Novel assay and animal model development
- Drug resistance, vaccine resistance, and viral evolution
- SARS-CoV-2 and other viral infections and respiratory diseases in adults and pediatric populations, including SARS-CoV-2/viral coinfections.

COMMITTEES

HIV DART ORGANIZING COMMITTEE



Raymond F. Schinazi
PhD, DSc, FAASLD
Emory University
USA



Monique Nijhuis
PhD
UMC Utrecht
Netherlands



Michaela Müller-Trutwin
PhD
Institut Pasteur
France



Hiroaki Mitsuya
MD, PhD
National Center for Global
Health & Medicine, Japan
NIH, USA



Savita Pahwa
MD
University of Miami Health
System
USA

Respi DART ORGANIZING COMMITTEE



Raymond F. Schinazi
PhD, DSc, FAASLD
Emory University
USA




Asuncion Mejias
MD, PhD
Nationwide Children's Hospital
USA



Susan Weiss
PhD
University of Pennsylvania
USA



Ralph Baric
PhD
University of North Carolina
USA



HIV DART SCIENTIFIC COMMITTEE

Eddy Arnold - Rutgers University, USA

Henry Chang - University of California Los Angeles, USA

Steven Deeks - University of California, San Francisco, USA

Carlos Del Rio - Emory University School of Medicine, USA

Matthias Götte - University of Alberta, Canada

Vince Marconi - Emory University, USA

Una O'Doherty - University of Pennsylvania, USA

Sarah Palmer - University of Sydney, Australia

Jose Rodriguez - University of Puerto Rico, USA

Michael Saag - University of Alabama at Birmingham, USA

Jonathan Schapiro - Sheba Medical Center, Israel

Nicolas Sluis-Cremer - University of Pittsburgh School of Medicine, USA

Mario Stevenson - University of Miami, USA

Ron Swanstrom - University of North Carolina, USA

RESPI DART SCIENTIFIC COMMITTEE

Jordan Feld - Toronto General Hospital Research Institute, Canada

Matthias Götte - University of Alberta, Canada

Ladislau Kovari - Wayne State University, USA

David Marchant - University of Alberta, Canada

Hiroaki Mitsuya - National Center for Global Health & Medicine, Japan & NIH, USA

Johan Neyts - Rega Institute for Medical Research, Belgium

Stefan Sarafianos - Emory University, USA

Kirsty Short - University of Queensland, Australia

Justin Stebbing - Imperial College London, England

Debby van Riel - Erasmus MC, Netherlands

ACCREDITATION STATEMENT




EMORY
UNIVERSITY
SCHOOL OF
MEDICINE


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Emory University School of Medicine and Informed Horizons Education, Inc. The Emory University School of Medicine Office of Continuing Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Emory University School of Medicine designates this live activity for a maximum of 13 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

IN PARTNERSHIP WITH



GENERAL INFORMATION



ABSTRACTS

Accepted abstracts are published in the abstract book available online on www.informedhorizonseducation.com.

BADGE POLICY

All registered delegates are provided with an identity badge. Please wear it at all times to ensure admission to the meeting, meals, and the leisure areas. Accompanying guests should also wear their badges for all meals and receptions.

CERTIFICATE OF ATTENDANCE

Certificates of attendance will be sent by e-mail upon request.

FEEDBACK FORM

Your feedback is very valuable to us and enables us to further improve this meeting. Feedback forms will be distributed during the workshop. Please complete these forms and return them to our staff members or registration desk.

GROUP PICTURE

A group photo will be taken during the meeting on Monday, December 5th at 12:35. Please follow IHE team members for further instructions.

MEETING APP

Download the EventsAIR app in the App Store or Google Play Store and use event app code

DART2022

to view the program, abstracts and attendance.

Use your PIN to login.

Android



Apple

MEETING SECRETARIAT

IHE serves as meeting secretariat for HIV & RESPI DART 2022. The IHE team will be available for all questions concerning the logistics of the meeting. You can find them at the registration desk.

SPEAKERS

Presenters are requested to submit their presentation by e-mail or on USB stick by November 28th. Any changes or updates need to be submitted to support@ihorizonsed.com or brought to the technicians table, located in the back of the meeting room, 24 hours prior to your presentation.

MOBILE PHONES

We kindly ask you to switch off or silence your mobile phones during the meeting sessions.

POSTER SESSION

The poster sessions will be held after lunch on Monday, December 5 (HIV DART) and Wednesday, December 7 (Respi DART) outside of the El Dorado ballroom and will be accessible throughout the meeting. Posters must be displayed throughout the entire meeting.

PRESENTATIONS & WEBCASTS

Video recordings of invited speakers will be made during the sessions. Presentation materials will be posted on www.informedhorizonseducation.com shortly after the meeting, pending speaker's permission.

SOCIAL PROGRAM

All breakfasts and lunches will be served at Talavera restaurant.

Opening reception: Dolphin Pool Reception Area
18:00, Sunday, December 4

HIV Dart
Poster reception: El Dorado Terrace
15:00, Monday, December 5

Respi Dart
Poster reception: El Dorado Terrace
15:00, Wednesday, December 7

Mexican Fiesta: Whale Watching Terrace
19:00, Wednesday, December 7

SCHOLARSHIP AWARD RECIPIENTS

Scholarships funded by the Raymond F. Schinazi and Family Foundation



Justin Hosten
Georgia Tech and
Emory University
USA



Aurelio Orta Reséndiz
Institut Pasteur
France




Erin Williams
University of Miami
USA

Eligible applicants include women, under-represented individuals, residents of low or middle-income countries, or a resource-limited setting, and individuals active in the fields of HIV and respiratory viruses.

PROGRAM PART 1

HIV DART 2022

LOS CABOS, MEXICO • 4-6 DECEMBER 2022



HIV DART - Sunday, December 4, 2022

OPENING SESSION

12:30 **Registration**

15:30 **Opening remarks**
Raymond F. Schinazi
Emory University, USA

SESSION 1 HIV latency, reservoirs and advances in cure strategies

Chairs Michaela Müller-Trutwin
Institut Pasteur, France

Serena Spudich
Yale University, USA

15:45 **Plenary lecture: Interactions between HIV and COVID-19**
Monica Gandhi
University of California San Francisco, USA

16:15 **Selection of HIV-1 reservoir cells during long-term ART**
Mathias Lichterfeld
Harvard University School of Medicine, USA

16:35 **When does the long-lived HIV-1 reservoir form?**
Sarah Joseph
University of North Carolina at Chapel Hill, USA

16:55 **SUMOylation by the SMC5/6 complex epigenetically silences unintegrated HIV-1 DNA leading to post-integration viral latency**
Bryan Cullen
Duke University, USA

17:15 **Panel discussion**

17:35 **End of day 1**

18:00 **Welcome reception**

HIV DART - Monday, December 5, 2022

Award Session

- Chairs Michael Saag
University of Alabama Birmingham, USA
- Hiroaki Mitsuya
NIH, USA
National Center for Global Health & Medicine, Japan
- 8:30 **Introduction and presentation of the Gertrude Elion Distinguished Lecturer Award**
Raymond F. Schinazi
Emory University, USA
- 8:40 **Gertrude Elion Distinguished Lecturer Award Lecture: “A tale of three scourges: Lessons from the early AIDS epidemic”**
James W. Curran
Emory University, USA

SESSION 2 Cutting edge developments in prevention and HIV therapeutics

- Chairs Steven Deeks
University of California San Francisco, USA
- Lishomwa Ndhlovu
Weill Cornell Medicine, USA
- 9:10 **Plenary lecture: Implementation and clinical management of injectable antiretrovirals for treatment**
Michael Saag
University of Alabama Birmingham, USA
- 9:40 **Impact of subtype on antiretroviral drugs for treatment and prevention**
Rami Kantor
Brown University, USA
- 10:00 **CCR5 in HIV prevention and cure**
Jonah Sacha
Oregon Health & Science University, USA
- 10:20 **Panel discussion**
- 10:30 **Break (30 min)**

SESSION 3 Industry session: Long-acting formulations (non-CME)

- Chairs Mario Stevenson
University of Miami, USA
- Victor Garcia-Martinez
University of North Carolina at Chapel Hill, USA
- 11:00 **ViiV long-acting formulations program**
Justin Koteff
ViiV Healthcare, USA
- 11:15 **ISL QD lymphocyte changes: results from a phase 2b dose-ranging study**
Todd Correll
Merck, USA
- 11:30 **Update on lenacapavir, a long acting first-in-class HIV capsid inhibitor**
Martin Rhee
Gilead Sciences, USA
- 11:45 **Panel discussion**

HIV DART - Monday, December 5, 2022

Oral Abstract Session I (non-CME)

- 11:55 **The pDC/IFN-I inflammatory pathway in HIV-1 pathogenesis and metabolic dysregulation**
Lishan Su
Institute of Human Virology, USA
- 12:05 **Selection of HIV-1 for resistance to fifth generation protease inhibitors reveals two independent pathways to high-level resistance**
Ronald Swanstrom
University of North Carolina at Chapel Hill, USA
- 12:15 **GRL142 binds to and impairs HIV-1-Integrase-Nuclear localizing signal and exerts potent activity against INSTI-resistant HIV-1**
Hiroaki Mitsuya
NIH, USA
National Center for Global Health & Medicine, Japan
- 12:25 **The first-in-human clinical trial of STP0404, a novel potent HIV-1 allosteric integrase inhibitor**
Xue Meng
ST Pharm Co Ltd, South Korea
- 12:35 **Group photo**
- 12:50 **Lunch & networking afternoon**
- 15:00 **Poster session**

SESSION 4 Immunity, vaccines, inflammation, neuroAIDS, and aging

- Chairs Vince Marconi
Emory University, USA
- Jonah Sacha
Oregon Health & Science University, USA
- 16:30 **Plenary lecture: Understanding neuroHIV in 2022: Neuroinflammation, viral persistence, and comorbidities**
Serena Spudich
Yale University, USA
- 17:00 **Insights from host epigenetic scars towards addressing HIV complications**
Lishomwa Ndhlovu
Weill Cornell Medicine, USA
- 17:20 **Keynote lecture: HIV cure: Bottlenecks and hope**
Michaela Müller-Trutwin
Institut Pasteur, France
- 17:50 **Panel discussion**
- 16:00 **End of day 2 and free evening**

HIV DART - Tuesday, December 6, 2022

SESSION 5 Conceptual shifts to mitigate the HIV crisis

Chairs James Curran
Emory University, USA

Mathias Lichterfeld
Harvard University School of Medicine, USA

- 8:30 **Plenary lecture: Role of macrophages in the context of HIV and the brain**
Victor Garcia-Martinez
University of North Carolina Chapel Hill, USA
- 9:00 **The HIV epidemic in Latin America: a time to reflect on the history of success and the challenges ahead**
Alvaro López Iñiguez
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico
- 9:20 **On the way to overcoming HIV/AIDS in Eastern Europe: challenges, scenarios and perspectives**
Alexey Mazus
National Virus Association, Russia

Oral Abstract Session II

- 9:40 **Development of an immunomodulatory AAV viral vector to minimizing adaptive immune responses to AAV-delivered broadly neutralizing antibodies**
James Termini
University of Miami, USA
- 9:50 **Identification of HLA-E binding HIV-1 and HIV-2 Env-derived peptides and cytokine modulation of NKG2A/C+ NK and NKG2A/C+ CD8+ T cells**
Aurelio Orta Reséndiz
Institut Pasteur, France
- 10:00 **Long-term ART-free SIV remission following allogeneic hematopoietic cell transplantation in Mauritian cynomolgus macaques**
Helen Wu
Vaccine Gene & Therapy Institute, Oregon Health & Science University, USA
- 10:10 **Therapeutic neutralizing monoclonal antibody administration protects against lethal yellow fever infection**
Gabriela Webb
Oregon Health and Science University, USA
- 10:20 **Combating yellow fever virus with 2'-Dihalo-Uridine nucleoside analogs**
Julia LeCher
Emory University, USA
- 10:30 **HIV-1 infection potentiates Alzheimer's disease pathology in a novel humanized APP knock-in mouse**
Pravin Yeapuri
University of Nebraska Medical Center, USA
- 10:40 **Break (30 min)**


Debate

- Chairs Sarah Joseph
University of North Carolina at Chapel Hill, USA
- Bryan Cullen
Duke University, USA
- 11:10 **Debate: Do we really need a cure for HIV when we already have ART?**
(ART) (Cure)
Mario Stevenson
University of Miami, USA
- Steven Deeks
University of California San Francisco
- 11:40 **Closing remarks**
Raymond F. Schinazi
Emory University, USA
- 11:55 **Meeting adjourns**

PROGRAM PART 2

Respi **DART** 2022

LOS CABOS, MEXICO • 6-8 DECEMBER 2022



Respi DART - Tuesday, December 6, 2022

OPENING SESSION

13:30 **Registration**

15:00 **Opening remarks**
Raymond F. Schinazi
Emory University, USA

SESSION 1 Advances in SARS-CoV-2 antiviral modalities

Chairs Claudia Morris
Emory University, USA

Ralph Baric
University of North Carolina Chapel Hill, USA

15:15 **Plenary lecture: Nirmatrelvir resistance in severe acute respiratory syndrome coronavirus 2**

Stefan Sarafianos
Emory University, USA

15:45 **Pre-clinical development of a broad-spectrum antiviral agent against SARS-CoV-2 3CL protease**

Ladislau Kovari
Wayne State University, USA

16:05 **Lipid-oxidizing B cells in successful vaccine responses despite immunosuppression**

Andrea Cox
Johns Hopkins University, USA

16:25 **Panel discussion**

16:35 **Break (15 min)**

SESSION 2 Respiratory viruses in children and inflammation

Chairs Susan Weiss
University of Pennsylvania, USA

Rachel Roper
East Carolina University, USA

16:50 **Plenary lecture: Successful research takes a village: Longitudinal surveillance of SARS-CoV-2 antibodies in pediatric healthcare workers**

Claudia Morris
Emory University, USA

17:20 **Inflammatory response to SARS-CoV-2 infection**

Rabindra Tirouvanziam
Emory University, USA

17:40 **End of day 1 and free evening**

Respi DART - Wednesday, December 7, 2022

Award Session

Chairs Michaela Müller-Trutwin Institut Pasteur, France Raymond F. Schinazi Emory University, USA

8:30 **Opening remarks and presentation of Barry-Wainberg DART Achievement Award**

Michaela Müller-Trutwin
Institut Pasteur, France

8:40 **Barry-Wainberg DART Achievement Award Lecture: Preventing viral pandemics: the case for an integrated trans disciplinary approach**

Christian Bréchet
University of South Florida, USA

SESSION 3 Animal disease models and long COVID-19

Chairs Stefan Sarafianos Emory University, USA Victor Garcia-Martinez University of North Carolina Chapel Hill, USA

9:10 **Plenary lecture: Therapeutic approaches to control acute and chronic emerging sarbecovirus pathogenesis**

Ralph Baric
University of North Carolina at Chapel Hill, USA

9:40 **Coronavirus animal models and pathogenesis**

Stanley Perlman
University of Iowa, USA

10:00 **Long COVID pathobiology and therapeutics: Where we are and where we need to go**

Michael Peluso
University of California San Francisco, USA

10:20 **Panel discussion (10 min)**

10:30 **Break (30 min)**

SESSION 4 Industry Session: Therapeutics against respiratory viruses: Clinical advances - an industry perspective (non-CME)

Chairs Jordan Feld University of Toronto, Canada Ladislau Kovari Wayne State University, USA

11:00 **The discovery of Paxlovid**

Dafydd Owen
Pfizer, USA

11:15 **Preclinical antiviral characterization of the novel SARS-CoV-2 3CL protease inhibitor ALG-097558**

Andreas Jekle
Aligos Therapeutics, USA

11:35 **Monoclonal antibodies for virus alphabet soup**

Wendy Yeh
Vir Biotechnology, USA

11:45 **New advances in RSV vaccine development**

Jay Lieberman
Meissa Vaccines, USA

12:00 **Panel discussion**

12:10 **Lunch & networking afternoon**

Respi DART - Wednesday, December 7, 2022

15:00 **Poster session**

SESSION 5 Host-virus interactions and basic science discoveries

Chairs Sabra Klein
Johns Hopkins University, USA

Rabindra Tirouvanziam
Emory University, USA

16:15 **Plenary lecture: Infection of primary nasal epithelial cells differentiates among human coronaviruses**

Susan Weiss
University of Pennsylvania, USA

16:45 **Interferons and SARS-CoV-2: Role in pathogenesis and therapeutics**

Jordan Feld
Toronto General Hospital Research Institute, Canada

Oral Abstract Session I

17:05 **Design of a ligand-targeted immunotherapy for treatment of influenza virus infections**

Philip Low
Purdue University, USA

17:15 **Development of small molecule entry inhibitors of influenza A viruses**

Lijun Rong
University of Illinois at Chicago, USA

17:25 **Development of human lung-like macrophages from primary block monocyte: a new platform for experimental studies of respiratory virus infection**

Justin Hosten
Emory University, USA

17:35 **End of day**

19:00 **Fiesta Mexicana / closing reception**

Respi DART - Thursday, December 8, 2022

SESSION 6 Immunology and advances in vaccine development

Chairs Stanley Perlman
University of Iowa, USA

Andrea Cox
Johns Hopkins University, USA

8:30 **Keynote lecture: Vaccines and therapeutics for monkeypox virus infections**

Rachel Roper
East Carolina University, USA

9:00 **Sex differences in immune responses against influenza infection and vaccination**

Sabra Klein
Johns Hopkins Bloomberg School of Public Health, USA

Oral Abstract Session II

9:20 **Development of highly potent SARS-CoV-2 Mpro inhibitors containing P1' fluorobenzohiazole moiety**

Hiroaki Mitsuya
NIH, USA
National Center for Global Health & Medicine, Japan

9:30 **Recovery of infectious SARS-CoV-2 from fecal specimens**

Leda Bassit
Emory University, USA

9:40 **Break (30 min)**

Oral Abstract Session III (non-CME)

10:10 **Molnupiravir exhibits a high barrier to the development of SARS-CoV-2 resistance *in vitro***

Julie Strizki
Merck & Co., Inc., USA

10:20 **Performance of serum liver biomarkers and algorithm combining plasma nuclear magnetic resonance (NMR) biomarkers and indicators of risk for future severe SARS-CoV-2 infection disease in the UK Biobank cohort (UKB)**

Thierry Poynard
Sorbonne University, France

10:30 **Differential antibody kinetics following SARS-CoV-2 infection, primary vaccination, and booster vaccination in an at-risk, longitudinal cohort**

Erin Williams
University of Miami, USA

10:40 **3D models of the human airway for rapid drug development**

Julia LeCher
Emory University, USA


10:50 **Closing remarks**

Raymond F. Schinazi
Emory University, USA

11:05 **Meeting adjourns**

**ORGANIZING COMMITTEE
&
INVITED SPEAKER BIOGRAPHIES**

BIOGRAPHIES



Ralph Baric

University of North Carolina at Chapel Hill, USA

Ralph S. Baric, PhD is the University of North Carolina William R. Kenan Jr. Distinguished Professor of Epidemiology in the Gillings School of Global Public Health and in the Microbiology and Immunology Department in the School of Medicine. He earned a BS in Zoology and a PhD in Microbiology from North Carolina State University. He performed postdoctoral research in virology and immunology at the University of Southern California before joining the faculty at the University of North Carolina. Dr. Baric's research focuses on the pathogenesis and emergence mechanisms of RNA viruses, focusing on coronaviruses, flaviviruses and noroviruses. His group has made seminal contributions in virus genetics, identifying host susceptibility genes that regulate virus pathogenesis and emergence, and studying mechanisms of virus cross species transmission, pathogenesis, and virulence, predicting in 2015 the emergence of future SARS-CoV-like epidemic strains. His laboratory participated in the development of several antiviral drugs (remdesivir, molnupiravir), therapeutic antibodies and vaccines (Moderna, Janssen) targeting the SARS-CoV2 virus which is responsible for the COVID19 pandemic. He is a member of the American Society for Microbiology (ASM) and American Society for Virology. He is a Harvey Weaver Scholar from the National Multiple Sclerosis Society and an Established Investigator from the American Heart Association. He served as chair-elect and subsequently the chair of ASM Division T, RNA viruses. He was a finalist for the World Technology Award, a senior editor for Plos Pathogens, and member of the Journal of Virology editorial board. He was a standing member of the NIH VirB study section from 2005-2009 and is a current member of NIH CMIA study section (2020-). He received the Innovation/Inspiration Award for UNC Faculty Research, the Lifetime achievement award from the Triangle Business Journal, Norma Berryhill Distinguished Lecturer, the UNC System's O' Max Gardner Award recipient and the North Carolina's Governor's Award recipient. He is a fellow of the American Academy for Microbiology, the National Academy of Sciences and the American Academy of Arts and Sciences. At the Congressional Biomedical Research Congress in early 2020, Baric updated the House of Representative members and staffs regarding the dangers of the SARS-CoV2 pandemic, including research priorities and strategies to mitigate risk.

BIOGRAPHIES



Christian Bréchet

University of South Florida, USA

Christian Bréchet, MD, PhD joined the USF Health Morsani College of Medicine part time as Senior Associate Dean for Research in Global Affairs, Associate Vice President for International Partnerships and Innovation, and Professor in the Division of Infectious Disease, Department of Internal Medicine. He is also executive director of the Tampa-based Romark Laboratories Institute for Medical Research. Since 2017, Dr. Bréchet has served as President of the Global Virus Network, a network of 48 research centers worldwide, headquartered in Baltimore.

Before serving as president of the Pasteur Institute from 2013 to 2017, Dr. Bréchet was vice president of medical and scientific affairs at Institut-Merieux, a company that develops new approaches to fight infectious diseases and cancers. He also served as the General Director of Inserm, the French national agency for biomedical research from 2002 to 2007. As professor of hepatology and cell biology at Necker School of Medicine, Paris Descartes University, he led the clinical department of liver diseases at Necker-Enfants Malades Hospital from 1997 to 2001.

Authoring more than 400 articles in medical and scientific journals, Dr. Bréchet was ranked by the Institute for Scientific Information as the 4th most cited author on the topic of hepatitis C. He has been recognized as an inventor on 18 patents, and helped create three biotechnology companies: Rarecells, ALFACT Innovation, and The Healthy Aging Company.

Dr. Bréchet's research activities have focused on viral hepatitis: hepatitis B (HBV) and C (HCV), particularly with regard to their role in liver cancer (Hepatocellular carcinoma: HCC) and to the molecular mechanisms that drive liver regeneration and cancer (in particular, cell cycle deregulation and the impact of oxydative stress). Additionally, Dr. Bréchet's research interests also include microbiomes, particularly in the area of microbiomes and viral infections. In this respect, he is a co-founder of the Microbiome, Immunology and Infection Control (MIIM) in the USF Pandemic Response Research Network (PRRN). This research hub focuses on enabling and connecting an interdisciplinary network of scientists at USF and globally. The hub's goals are to develop precision therapies and interventions that target the human microbiome to maintain and restore human health against COVID-19 and future such pandemics. Dr. Bréchet is also head of the USF Initiative on Microbiomes. He has been the member of numerous scientific committees and societies and has received prestigious awards.

BIOGRAPHIES



Andrea Cox
Johns Hopkins University, USA

Andrea Cox is a Professor of Medicine and Oncology at The Johns Hopkins University School of Medicine in Baltimore. She earned her Ph.D. studying T cell immunology at The University of Virginia. She subsequently completed an M.D. and then Internal Medicine and Infectious Disease training at Johns Hopkins. Her laboratory investigates human immune responses to SARS-CoV-2, hepatitis C virus (HCV), hepatitis B virus (HBV), and HIV, including mechanisms through which these infections stimulate and evade immune responses, and in HCV vaccine development. She is also the co-director of the Johns Hopkins SARS-CoV-2 Pathogenesis and Immunity Center with Sabra Klein. As a member of the Viral Hepatitis Center in the Division of Infectious Diseases, she specializes in the treatment of patients with viruses including hepatitis virus infections, SAR-CoV-2, and HIV. She was the principal investigator on the first prophylactic HCV vaccine trial ever implemented in an at-risk population, and is the lead immunologist on an ACTG trial of HBV vaccines in HIV infected patients.



Bryan Cullen
Duke University, USA

Bryan R. Cullen obtained a B.Sc. in Biochemistry from Warwick University in the UK and a M.Sc. in Virology from the University of Birmingham before moving to the USA, where he obtained a Ph.D. in Microbiology from Rutgers University. In 1987, he was recruited to Duke University Medical Center as a Howard Hughes Medical Institute Investigator. He currently holds a James B. Duke Professorship in the Department of Molecular Genetics and Microbiology at Duke. Dr. Cullen’s research interests focus on the use of viruses, especially HIV-1, as genetic tools to understand the molecular biology of eukaryotic cells, focusing particularly on RNA-sequence mediated gene regulation. Currently, his laboratory is studying the regulation of viral mRNA expression by epitranscriptomic modifications and using CRISPR/Cas-mediated gene editing as a tool to identify cellular factors that regulate viral gene expression. Recently, this has resulted in the identification of cellular factors that induce the epigenetic repression of HIV-1, resulting in latent infections. Dr. Cullen has published over 330 research papers and was listed as one of the worlds most highly cited scientists by Thomson Reuters.

BIOGRAPHIES



James Curran

Emory University, USA

Jim Curran joined the Rollins School of Public Health (RSPH) as dean and professor of epidemiology in 1995, following 25 years of leadership at the Centers for Disease Control and Prevention (CDC). He is emeritus director of the Emory Center for Aids Research, and holds faculty appointments in the Emory School of Medicine and the Nell Hodgson Woodruff School of Nursing.

Curran is internationally known for heading the 1981 CDC Task Force charged with investigating the first cases of what later became known as AIDS and was a key figure in the interactions between the CDC and the NIH during the two agencies' efforts to investigate the epidemiology and cause of HIV. While at the CDC, he attained the rank of assistant surgeon general.

After graduating from the University of Notre Dame, Curran received his MD from the University of Michigan and a master of public health from Harvard University. Author or co-author of more than 300 scholarly publications, he was elected to the Institute of Medicine of the National Academy of Science (now the National Academy of Medicine) in 1993.

Curran has served in numerous leadership positions, including Chair of the Office of AIDS Research (OAR) Council and Chair or Co-Chair of two IOM Committees on International HIV policies and programs. In 2015 he was elected to the American Academy of Arts and Sciences. He has also been a member of the Board of Public Health, State of Georgia since 2011 and served as Chair since 2019.

In 2009, the Rollins School of Public Health Dean's position was named the James W. Curran Dean of Public Health in his honor.

On July 1, 2022 Curran stepped down as Dean and remains on the faculty of the Rollins School of Public Health as Emeritus Dean and Professor of Epidemiology and Global Health.


BIOGRAPHIES



Steven Deeks

University of California, San Francisco, USA

Steven G. Deeks, MD, is a Professor of Medicine in Residence at the University of California, San Francisco (UCSF) and a faculty member in the Division of HIV, Infectious Diseases and Global Medicine at Zuckerberg San Francisco General Hospital. Dr. Deeks has been engaged in HIV research and clinical care since 1993. He is a recognized expert on HIV-associated immune dysfunction and its impact on HIV persistence (the “reservoir”) and health during antiretroviral therapy. Dr. Deeks has published over 500 peer-review articles, editorials and invited reviews on these and related topics. He has been the recipient of several NIH grants, and one of the principal investigators of DARE (the Delaney AIDS Research Enterprise), which is an NIH-funded international collaborative aimed at developing therapeutic interventions to cure HIV infection. He is a member of the Board of Directors for the UCSF-based amfAR Institute for HIV Cure Research. He is the co-chair of the “Towards an HIV Cure” International Working Group and a former co-chair of the NIH Office of AIDS Research Toward a Cure Planning Group. He was elected to the American Society for Clinical Investigation (ASCI) and Association of American Physicians (AAP). He is the editor-in-chief of Current Opinion in HIV and AIDS, and serves on the Scientific Advisory Board for Science Translational Medicine and the Advisory Board for EBioMedicine. In addition to his clinical and translational investigation, Dr. Deeks maintains a primary care clinic for HIV infected patients. He is a former member of the Office of AIDS Research Advisory Council (ORAC) and of the Department on Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents.



Jordan Feld

University of Toronto, Canada

Dr. Feld trained in GI and Hepatology at the University of Toronto and did post-doctoral training in the Liver Diseases Branch at the National Institutes of Health in laboratory and clinical research in viral hepatitis. After completing a Masters in Public Health at the Johns Hopkins Bloomberg School of Public Health, he returned to Toronto. He is a Professor of Medicine at the University of Toronto and holds the R. Phelan Chair in Translational Liver Research as a clinician-scientist at the Toronto Centre for Liver Disease in the Toronto General Hospital where he leads a large clinical and translational research program focused primarily on viral hepatitis and its complications.

BIOGRAPHIES



Victor Garcia-Martinez

University of North Carolina at Chapel Hill, USA

J. Victor Garcia-Martinez received his Ph.D. in Chemistry from Georgetown University. He received postdoctoral training at the National Cancer Institute, an institute within the U.S. National Institutes of Health (NIH) and the Massachusetts Institute of Technology (MIT). Dr. Garcia was a Research Associate at the Fred Hutchinson Cancer Research Center in Seattle. He was an Assistant, and subsequently, an Associate Member of St. Jude Children's Research Hospital and a Professor of Medicine at U. T. Southwestern in Dallas.

Dr. Garcia is currently a Professor of Medicine in the Center for AIDS Research (CFAR), the Institute for Global Health & Infectious Diseases (IGHID), and the Division of Infectious Diseases in the Department of Medicine all at the University of North Carolina at Chapel Hill. Throughout his career, Dr. Garcia has made seminal contributions to the understanding of HIV pathogenesis, specifically the function of Nef, which is an important determinant of HIV pathogenesis and disease progression. More recently, Dr. Garcia's group has established an outstanding track record in the development, implementation and use of humanized mice. Since their landmark publications describing the humanized BLT, TOM, MOM and LoM mouse models have been widely used to address key questions of HIV infection, transmission, prevention, persistence and cure and most recently to study the pathogenesis, treatment and prevention of SARS-CoV-2.


BIOGRAPHIES



Monica Gandhi

University of California, San Francisco, USA

Monica Gandhi MD, MPH is an Infectious Diseases doctor, Professor of Medicine and Associate Chief in the Division of HIV, Infectious Diseases, and Global Medicine at the University of California, San Francisco (UCSF). She is also the Director of the UCSF Center for AIDS Research (CFAR) and the Medical Director of the HIV Clinic ("Ward 86") at San Francisco General Hospital. Her research focuses on HIV and women and adherence measurement in HIV treatment and prevention and most recently, on how to mitigate the COVID-19 pandemic.



Andreas Jekle

Aligos Therapeutics, USA

Andreas Jekle is a virologist at Aligos Therapeutics focusing on the preclinical and clinical virology for their HBV capsid assembly modulator ALG-000184 and SARS-CoV-2 protease inhibitor ALG-097558. He received his PhD in cell biology in 2000 from the Eberhard-Karls University in Tübingen, Germany and his postdoctoral training at the J David Gladstone Institute/UCSF, focusing on HIV pathogenesis. Since 2003, he worked on antiviral drug discovery (HIV, Dengue, HCV, Influenza, RSV, Rhinovirus, HBV and SARS-CoV-2) at Roche Palo Alto, Novabay Pharma, Alios Biopharma, and since 2018 Aligos Therapeutics.



Sarah Joseph

University of North Carolina at Chapel Hill, USA

Dr. Sarah Joseph is a virologist and evolutionary biologist with extensive experience examining HIV-1 in different compartments of the body and in the long-lived HIV-1 reservoir. Dr. Joseph received her Ph.D. from the University of Texas at Austin and was a postdoc at the University of North Carolina where she is now an Assistant Professor in the Department of Microbiology & Immunology. Dr. Joseph utilizes both traditional and next generation sequencing techniques to characterize HIV-1 populations in patient samples and to infer information about the evolutionary pressures shaping HIV-1 populations. This approach has revealed important information about the nature of HIV-1 transmission, colonization of the CNS and establishment of viral reservoirs.


BIOGRAPHIES



Rami Kantor

Brown University, USA

Rami Kantor MD is an internal medicine and infectious diseases physician-scientist, Professor of Medicine in the Division of Infectious Diseases at Brown University in Providence, RI, USA. He completed his internal medicine residency at the Sheba Medical Center in Israel, and was recruited to Brown University in 2005, after conducting a post-doctoral HIV research fellowship at Stanford University. He completed his clinical infectious diseases training at Brown University. He is a clinician who treats inpatients and outpatients. He directs the Drug Resistance Laboratory at the Providence-Boston Center for AIDS Research (CFAR), and co-Directs the CFAR Basic Science Core. He is past Chair of the HIV and Comorbidities and Clinical Studies US NIH study section. He is a member of the US DHHS Guidelines Panel for HIV Treatment in Adults and Adolescents, and an Editorial Board Member and a Deputy Editor of the Journal of the International AIDS Society. Dr. Kantor's NIH-funded, multidisciplinary clinical and basic science research focuses on the evolution of antiretroviral resistance, treatment monitoring, and transmission in patients with HIV from different populations and in different settings globally, and he is part of national and international collaborations and networks. He is also committed to teaching and mentoring and has mentored numerous undergraduate and graduate students, post-doctoral fellows and junior faculty."




Sabra Klein

Johns Hopkins University, USA

Dr. Klein is a Professor of Molecular Microbiology & Immunology, Biochemistry & Molecular Biology, and International Health at the Johns Hopkins Bloomberg School of Public Health and Department of Medicine at the Johns Hopkins School of Medicine. She is an expert on sex and gender differences in immune responses and susceptibility to infection and vaccination. She currently has over 150 peer-reviewed publications, authored several book chapters, and edited three books on the broad topics of sex differences in response to infection and treatments for infectious diseases. During the 2009 influenza pandemic, she was commissioned by the WHO to evaluate and publish a report on the impact of sex, gender, and pregnancy on the outcome of influenza virus infection. During the current COVID-19 pandemic, Dr. Klein has written commentaries for several journals and been interviewed by several major news media outlets about sex differences in immunity, disease outcomes, and responses to vaccines. She is PI of the Johns Hopkins Specialized Center for Research Excellence (SCORE) in sex and age differences in immunity to influenza, MPI of the Johns Hopkins COVID-19 Serology Center of Excellence, MPI of an NIH Merit Award to study sex differences in the pathogenesis of respiratory microbial infections, co-chair of the advisory board of the Johns Hopkins Building Interdisciplinary Research Careers in Women's Health, member of the Advisory Committee on Research on Women's Health at NIH, co-director of the Johns Hopkins Center for Women's Health, Sex, and Gender Research, and a fellow of the American Academy of Microbiology and the American Association for the Advancement of Science.

BIOGRAPHIES



Ladislau Kovari

Wayne State University, USA

Dr. Ladislau Kovari obtained his Ph.D. in Microbiology and Immunology from the University of Tennessee, USA. Before his doctoral training, he studied Biochemistry (B.S. and M.S. degrees) at the University of Bucharest, Romania. He completed his postdoctoral studies at Purdue University, USA, and was a team member solving the crystal structure of the HIV-1 capsid protein p24. He has been a faculty member at Wayne State University School of Medicine in Detroit, Michigan, USA, for the past 25 years. As a Professor of Biochemistry, Microbiology, and Immunology, he has focused his research on viral proteases, antiviral drug design, mechanisms of antiviral resistance, and X-ray crystallographic studies of protein-ligand complexes. Dr. Kovari also serves as Associate Chair of the Department of Biochemistry, Microbiology, and Immunology at Wayne State University School of Medicine. His earlier work has centered on HIV-1 protease and integrase drug resistance mechanisms. Dr. Kovari is on sabbatical leave at the University of Michigan, USA, this year. He completed two previous sabbaticals, the first at Vertex Pharmaceuticals, Inc., working as a member of the HCV drug telaprevir team, and a second sabbatical at NIH, working on next-generation HIV-1 protease inhibitors in the laboratory of Dr. Hiroaki Mitsuya. His current research focus involves studies of SARS-CoV-2 antivirals, particularly the design, synthesis, and testing of CoV-2 3CL and PL protease inhibitors in collaboration with Dr. Raymond Schinazi's group at Emory University and Dr. Navnath Gavande's group at Wayne State University.



Mathias Lichterfeld

Harvard Medical School, USA

Dr. Mathias Lichterfeld is an infectious disease physician who works as a basic science and translational investigator, a clinical care provider, and a mentor and educator for residents and clinical/research fellows. Dr. Lichterfeld is an Associate Professor of Medicine at Harvard Medical School and Co-Director of the Harvard University Center for AIDS Research (CFAR) Program on HIV Education. He is also a staff physician in the Infectious Disease Division of the Brigham and Women's Hospital (BWH) and MGH: an Associate Member of the Ragon Institute of MGH, MIT and Harvard; and an Associate Member of the Board Institute of MIT and Harvard.

BIOGRAPHIES



Jay Lieberman
Meissa Vaccines, USA

Jay M. Lieberman, MD is Vice President of Clinical Development at Meissa Vaccines. Before joining Meissa, he was a Director of Medical Affairs at ICON plc (formerly PRA Health Sciences), where he served as a Medical Monitor and Therapeutic Expert for clinical trials of a variety of vaccines and infectious disease therapies in children and adults. Previously, Jay was a Regional Medical Director for Merck Vaccines. Prior to that, he was Medical Director of Infectious Diseases at Quest Diagnostics and Laboratory Director for Focus Diagnostics, an infectious diseases reference laboratory owned by Quest. Jay is a graduate of Princeton University and the New York University School of Medicine. He is a specialist in pediatric infectious diseases, having completed his residency training in pediatrics at Children’s Hospital of Los Angeles (CHLA) and fellowship training in pediatric infectious diseases at CHLA and at Harbor-UCLA Medical Center. He served as professor of clinical pediatrics at the University of California, Irvine (UCI) and chief of infectious diseases at Miller Children’s Hospital in Long Beach. While there, his clinical research activities included the evaluation of vaccines, other biologics, and antimicrobials in children, and he was honored to be a seven-time recipient of the Golden Apple Teaching Award from the UCI School of Medicine and a four-time recipient of the Faculty Teaching Award from Miller Children’s Hospital.



Alvaro López Iñiguez
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán,
Mexico

Alvaro López Iñiguez is a Mexican infectious disease specialist in care for people with HIV infection. He was born in Guadalajara Jalisco where he grew up and trained as an internist, later he studied at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City where he studied infectious diseases, and did a fellowship in HIV specialized clinical care and obtained a master’s degree in research.

He is passionate about the study of infectious diseases and especially HIV infection. The clinical care of individuals with HIV is an opportunity to provide specialized medical care and also an opportunity to actively participate as an activist in search of equity, justice and against stigma.

BIOGRAPHIES



Alexey Mazus

National Virus Association, Russia

Dr. Mazus graduated from the A. I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia, in 1993. His major scientific and clinical interest are infectious diseases including HIV/AIDS, HAART. Необходимо добавить где получены степени кандидата и доктора наук.

Since 2000 Alexey Dr Mazus is Head of the Moscow Centre for HIV/AIDS Prevention and Treatment. Presently, he serves as Chief Specialist in HIV at the Ministry of Health of the Russian Federation and Head the Moscow Centre for HIV/AIDS Prevention and Treatment, Head of Chair of the National Virus Association and, Director of the International Educational and Methodological Center of Virology of the Medical Institute of the Peoples' Friendship University of Russia (RUDN).

Dr. Mazus author of many publications on HIV/AIDS in distinguished scientific journals, methodical and clinical guidelines. Main research topics are epidemiological situation in Moscow and Russia, the features of the HIV/AIDS in Russia, studies of HIV/AIDS prevention, treatment and control effectiveness, HIV prevention and treatment in pregnant women, youth education and public health programs management.

In 2022 one of his publications - «Sputnik V protection from COVID-19 of HIV-infected individuals under ART» - published in EclinicalMedicine (The Lancet) Journal was the first publication in the world to directly confirm the effectiveness of COVID-19 vaccination program among people living with HIV.

BIOGRAPHIES



Asuncion Mejias

Nationwide Children's Hospital, USA

Asuncion Mejias, MD, PhD is a principal investigator in the Center for Vaccines and Immunity at The Research Institute at Nationwide Children's Hospital. She is an Associate Professor of Pediatrics at The Ohio State University College of Medicine and faculty from the Division of Pediatric Infectious Diseases. Her research program focuses on the immunopathogenesis of respiratory viral infections and the mechanisms of viral-host interaction using a multidisciplinary approach, with particular emphasis on respiratory syncytial virus (RSV) infection.



Hiroaki Mitsuya

National Center for Global Health & Medicine, Japan
NIH, USA

Dr. Hiroaki Mitsuya obtained his M.D. and Ph.D. in Kumamoto University School of Medicine in Japan. After receiving immunology/hematology/oncology training at Kumamoto University Hospital, Dr. Mitsuya joined the National Cancer Institute in 1982 and began studying the outcome of infection by human T cell leukemia virus type 1, the first known human pathogenic retrovirus. In 1984, Dr. Mitsuya steered his attention to human immunodeficiency virus or HIV and played a critical role in the discovery and development of the first three drugs for AIDS and HIV infection [zidovudine (AZT), didanosine (ddI), and zalcitabine (ddC)]. Dr. Mitsuya has since been a leading researcher in the area of development of AIDS therapeutics and study of HIV resistance. Recently he has played a major role in the discovery and development of the next generation anti-HIV drug, darunavir.

Dr. Mitsuya has been Chief, Experimental Retrovirology Section, NCI, USA since 1991; and Chairman and Professor, Departments of Hematology and Rheumatology, and Director, Division of Infectious Diseases, Kumamoto University School of Medicine, Kumamoto, Japan since 1997. Dr. Mitsuya has also assumed a position of Director-General in the International Center for Clinical Research, National Center for Global Health and Medicine, Tokyo, Japan since January 2012.

BIOGRAPHIES



Claudia Morris
Emory University, USA

Dr. Claudia R. Morris, MD is a Professor of Pediatrics and Emergency Medicine at Emory University School of Medicine and holds the Wilbur Fisk Glenn Jr. Distinguished Faculty Chair for Clinical & Translational Research. She is the Director of Research for the Division of Pediatric Emergency Medicine (PEM) at Emory and is also the Co-Director of the Emory+Children’s Center for Clinical & Translational Research. Clinically she is an attending physician in PEM at Children’s Healthcare of Atlanta. She received her medical degree at Eastern Virginia Medical School, and completed her residency training in Pediatrics at Children’s Hospital Oakland (now UCSF-Benioff Children’s Hospital Oakland). She went on to do a chief resident year, as well as a fellowship in PEM at Children’s Hospital Oakland, and remained on as faculty until her relocation to Emory in 2012. Dr. Morris has been actively involved in clinical and translational research for over 2 decades and has a successful track record of extramural funding, clinical trials leadership, high-impact publications and mentorship of fellows, medical students and junior faculty. Dr. Morris is the site PI from the San Francisco-Oakland, Providence, Atlanta Research Collaborative (SPARC) node within the Pediatric Emergency Care Applied Research Network (PECARN), that includes all 3 Children’s pediatric emergency department (ED) campuses in Atlanta evaluating over 240,000 children annually, in a network effort to identify best practices for the prevention and management of acute illnesses and injuries in children across the continuum of emergency medicine health care. She has built a research infrastructure within the ED over the last decade that insures successful enrollment into research projects including patients with suspected COVID-19 into the Rapid Acceleration of Diagnostics (RADx) program and the international Pediatric Emergency Research Network (PERN) while they are evaluated clinically in the ED, and led various ED-based HIV screening studies. Successful research takes a village.



Michaela Müller-Trutwin
Institut Pasteur, France

Michaela Müller-Trutwin is Professor at Institut Pasteur and head of the “HIV, Inflammation and Persistence” Unit. She studied Biology at the University in Bonn and obtained her PhD from Paris-University, France (Barré-Sinoussi lab). She worked at Research institutes in West- and Central-Africa. She served as chair of the “Nonhuman primate models working group” and within the “innate immunity coordinated action” at the ANRS. Among other duties, she currently serves as the chair of the coordinated action on HIV basic research at the ANRS-MIE and as Vice-president of the Scientific Council at Institut Pasteur. Her research has been focused on molecular and immunological mechanisms of viral evolution and control, with a focus on HIV/AIDS. She contributed to understand the worldwide diversity of HIV and SIV viruses with an impact on patient monitoring and vaccine candidate design. Subsequently, her team has developed numerous tools for studying nonpathogenic SIV infection in natural hosts. Her studies were among those that provided the evidence that inflammation is the driving force of progression toward disease. More recently, her team uncovered the capacity of NK cells to control SIV replication in lymph nodes. The studies are performed with the ultimate aim to contribute to the development of preventive and curative approaches in humans. Her work has been honored by awards, such as by the French Medical Research Foundation.

BIOGRAPHIES



Lishomwa Ndhlovu

Weill Cornell Medicine, USA

Lishomwa (Lish) Ndhlovu MD, PhD is a Professor of Immunology in Medicine in the Division of Infectious Diseases at Weill Cornell Medicine. The thrust of his research program is confronting the challenges of HIV and aging and is developing specific strategies to prevent, slow or eliminate complications associated with HIV. His team combines immunology, virology and epigenetic methods exploring molecular mechanism of HIV pathogenesis and persistence through pre-clinical and clinical investigations and has expanded towards finding an HIV cure. He has also become increasingly involved in bringing the same urgency and focus to the COVID-19 pandemic and exploits immuno-epigenetic approaches to resolve molecular mechanisms regulating SARS-CoV-2 infection across tissues and cell types in people with and without HIV. His lab is largely supported by individual and consortia grants from the NIH. He is a member of the International Neuro-HIV Cure Consortium and Co-leader of the \$26.5 million NIH - funded Martin Delaney Collaboratory for HIV Cure "HOPE" and NIDA funded U01-SCORCH program documenting single cell opioid responses in the brain in the setting of HIV. He is an elected Fellow of the American Academy of Microbiology and serves as Co-Editor in Chief of the journal, AIDS Research and Human Retroviruses.



Dafydd Owen

Pfizer, USA

Dafydd Owen has twenty-three years of experience as a medicinal chemist in the design and synthesis of drug-like molecules for Pfizer at its Sandwich UK and Cambridge MA research sites. He obtained his first degree at Imperial College in 1994 before moving to the University of Cambridge to gain a Ph.D under the supervision of Professor Steve Ley FRS in 1997. Having won a research fellowship for postdoctoral work, he spent 1998 with Professor Leo Paquette at Ohio State University. During his research career he has delivered over one hundred invited lectures and is an author on over seventy research papers and patents. He has made contributions seven clinical candidates during his career at Pfizer. He serves as a board member of the Structural Genomics Consortium and sits on the editorial advisory board of the Journal of Medicinal Chemistry. He currently works in an outward looking, academically collaborative group for Pfizer looking to better understand protein families and their role in human disease through chemistry.

Most recently he led Pfizer's oral protease inhibitor program that ultimately delivered PAXLOVID, the world's first oral antiviral therapy for the treatment of COVID-19.

BIOGRAPHIES



Savita Pahwa

University of Miami Health System, USA

Savita Pahwa is a physician scientist currently appointed as Professor in the department of Microbiology and Immunology with secondary appointments in Pediatrics and Medicine at the University of Miami School of Medicine in Florida, USA. Dr Pahwa is a graduate of Lady Harding Medical College in New Delhi, India. She trained as an immunologist at the Memorial Hospital and Sloan Kettering Institute in New York City and directed the Allergy/Immunology Program at North Shore University Hospital in Long Island, NY for several years. Currently she is Director of the Miami Center for AIDS Research (CFAR), and head of the CFAR's Laboratory Sciences Core and a member of the Miami Clinical Trials Unit for the ACTG and IMPAACT networks. Dr Pahwa has >300 publications including book chapters and has served on several HIV/AIDS review panels. One of her current scientific interests relates to the impact of inflammation in the context of HIV infection, aging, and comorbidities such as cardiovascular disease and neurologic impairment. To probe the immune system she has investigated immune responses to influenza vaccine in individuals of different ages with and without HIV infection. She is performing additional studies to understand underlying mechanisms impacting immunity in aging in the context of SIV infection in the non-human primate model. Dr Pahwa's research is supported by grants from the NIH.




Michael Peluso

University of California, San Francisco, USA

Dr. Peluso is an infectious disease physician at the University of California, San Francisco. Prior to COVID, his research focus was on the chronic sequelae of HIV infection. When the SARS-CoV-2 pandemic emerged, Dr. Peluso led the efforts to implement the Long-term Impact of Infection with Novel Coronavirus (LIINC, pronounced "link") study at San Francisco General Hospital, based on the hypothesis that COVID could have a long-term impact on health and well-being. LIINC was one of the first post-COVID cohorts in the U.S. and now includes hundreds of individuals with and without Long COVID, many of whom have been followed for more than 2 years. He leads projects within LIINC aimed at understanding the biological mechanisms that drive Long COVID and is also responsible for implementation of the UCSF enrolling sites for the NIH's RECOVER initiative.

BIOGRAPHIES



Stanley Perlman
University of Iowa, USA

Dr. Perlman received his Ph.D. in Biophysics from M.I.T., Cambridge, Massachusetts and his M.D. from the University of Miami, Miami, Florida. He was trained in Pediatrics and Pediatric Infectious Diseases at Boston Children's Hospital, Boston, Massachusetts. He is a member of the VRBPAC of the FDA and the COVID-19 Advisory Committee of the ACIP (Advisory Committee on Immunization Practices).

His current research efforts are focused on coronavirus pathogenesis, including virus-induced demyelination and the Severe Acute Respiratory Syndrome (SARS), the Middle East Respiratory Syndrome (MERS) and COVID-19. His laboratory has developed several novel animal models useful for studying pathogenesis and evaluating vaccines and antiviral therapies. His studies are directed at understanding why aged patients and mice developed more severe disease than younger individuals after infection with SARS-CoV or SARS-CoV-2 and also on why there is a male predominance in patients with more severe disease after infection with SARS-CoV, MERS-CoV or SARS-CoV-2. He and his colleagues demonstrated that transduction of mice with an adenovirus expressing the human receptor for MERS-CoV, DPP4, rendered them sensitive to infection, providing the first rodent model useful for studying MERS. Similar approaches have been used to develop several mouse models for COVID-19. Among other topics, his research is now focusing on the loss of sense of smell (anosmia) and taste (ageusia) observed in patients with COVID-19.



Martin Rhee
Gilead Sciences, USA

Dr. Martin Rhee is currently an Executive Director in Clinical Development in Virology at Gilead Sciences, leading the clinical development of lenacapavir, the first-in-class long acting HIV capsid inhibitor. Over the past decade, Dr. Rhee made significant contributions in bringing many of Gilead's novel HIV medicines to people with HIV. Dr. Rhee received a medical degree from Seoul National University in Korea and completed his residency in internal medicine at Dartmouth Hitchcock Medical Center and fellowship in infectious disease at Tufts Medical Center.


BIOGRAPHIES



Rachel Roper

East Carolina University, USA

Dr. Roper is a Professor of Microbiology and Immunology at East Carolina University (ECU) in the Brody School of Medicine. She received her B.S. from Texas A & M University and her M.S. and Ph.D. from the University of Rochester, School of Medicine and Dentistry where she received the M.A. Hare Research Excellence Award. During her post-doctoral training at the National Institutes of Health Lab of Viral Disease, she was awarded the NIH Fellows Award for Research Excellence. Dr. Roper has studied poxvirus virulence genes, genomics, and vaccines, including oncolytic viruses, and her publications have been cited over 7,000 times. She has been funded by NIH, the NSF, and Foundations and is a member of the National Academy of Inventors, and Co-Chair of the Global Virus Network Monkeypox Task Force. She serves on the American Society for Microbiology Inclusive Diversity with Equity, Access, and Accountability (IDEAA) Committee of the Board and is an ECU Woman of Distinction. She has served on numerous national and international Grant Panels and Editorial Boards.



Michael Saag

University of Alabama Birmingham, USA

Dr. Saag is Professor Emeritus of Medicine, Microbiology and Public Health at the University of Alabama at Birmingham. During his fellowship in Infectious Diseases, Dr. Saag conceived the concept of a comprehensive HIV outpatient (1917) clinic dedicated to the provision of comprehensive patient care in conjunction with the conduct of high-quality clinic trials, basic science, and clinical outcomes research. Over the last 35 years, the clinic has treated more than 12,000 patients and has become recognized as one of the best sites for clinical research and care in the United States. Dr. Saag has published over 500 articles in peer reviewed journals, including the first description of the quasispecies nature of HIV (Nature, 1988), the first use of viral load in clinical practice (Science, 1993), the first description of the rapid dynamics of viral replication (Nature, 1995), the first guidelines for use of viral load in practice (Nature Medicine, 1996), the first proof of concept of fusion inhibition as a therapeutic option (Nature Medicine, 1998), and directed the 'first-in-patient' studies of 7 of the 25 antiretroviral drugs currently on the market. Dr. Saag has received the Myrtle Wreath Award from Hadassah, was listed as one of the top ten cited HIV researchers by Science (1996), and received multiple Argus Awards for Best Lectures to the 1st year medical students at UAB. In 2014, Dr. Saag was named the Castle-Connolly National Physician of the Year Award for Clinical Excellence and was inducted into the Alabama Healthcare Hall of Fame. He is Co-Editor of the Sanford Guide. During the COVID epidemic, Dr. Saag has appeared frequently on CNN, MSNBC, Yahoo Finance, and the Paul Finebaum Show and has published frequent OpEd features in the Washington Post. Dr. Saag published a memoir entitled, "Positive: One doctor's encounters with death, life, and the US Healthcare System," which is in its third printing.

BIOGRAPHIES



Jonah Sacha

Oregon Health and Science University, USA

Jonah Sacha, Ph.D., graduated cum laude from the University of Missouri-Columbia in 2003 with a B.A. in German and B.S. in Biology. After receiving his Ph.D. in Medical Microbiology & Immunology from the University of Wisconsin-Madison in 2007, he joined the faculty at UW-Madison where he researched the characteristics of effective retrovirus-specific CD8+ and CD4+ T cells. In 2011, he joined the Oregon Health & Science University and has appointments in both the Vaccine & Gene Therapy Institute and Oregon National Primate Research Center. He currently holds the rank of Professor and his laboratory is focused on identifying new therapeutic modalities for the prevention, treatment, and cure of infectious diseases.



Stefan Sarafianos

Emory University, USA

Stefan Sarafianos holds the Nahmias-Schinazi Distinguished Professor endowed chair at Emory University, where he serves as Associate Director of the Laboratory of Biochemical Pharmacology. He also serves as Co-Director of the B-HIVE U54 Center at Seattle Children's Hospital. Since 1993, he has published >185 manuscripts in retroviral structural biology, biochemistry, and virology. The structures solved through his collaborations are seminal in the field of HIV drug resistance and DNA polymerases. His lab develops novel inhibitors and characterizes their mechanisms of inhibition and resistance. Notably, his work with EFdA has resulted in >25 publications and licensing by Merck. Dr. Sarafianos was the first to provide a structural model for the SARS-CoV RNA-dependent RNA polymerase and express, purify, and characterize the SARS Co-V RNA-dependent RNA polymerase. Since 2003, his work with coronaviruses has focused on discovery of antivirals that block RNA unwinding and viral entry. Recently, his lab has focused on developing tools for extensive screening and mechanistic characterization of inhibition, drug resistance, and basic biology of coronaviruses, including SARS-CoV-2.

BIOGRAPHIES



Raymond F. Schinazi

Emory University, USA

Dr. Raymond F. Schinazi is the Frances Winship Walters Professor of Pediatrics and Director of the Laboratory of Biochemical Pharmacology at Emory University & Children’s Healthcare of Atlanta. Dr. Schinazi has authored over 500 peer-reviewed papers and 7 books and holds over 100 issued US patents, which have resulted in 26 New Drug Applications (NDA). A world leader in nucleoside chemistry, Dr. Schinazi is best known for his pioneering work on HIV, HBV and HCV drugs d4T (stavudine), 3TC (lamivudine), FTC (emtricitabine), LdT (telbivudine), and most recently the precursor of sofosbuvir (Sovaldi), which are approved by the US FDA. More than 94% of HIV-infected individuals in the US on combination therapy take at least one of the drugs he invented. Dr. Schinazi served on the Presidential Commission on AIDS.

He is the recipient of numerous awards including the 2016 Humanitarian Award from the Institute of Human Virology, the 2016 Scrip Lifetime Achievement Award, State of the Art Award from the 2017 Paris Hepatology Conference, and 2017 Excellence Prize from Journées Québécoises, McGill University. In 2018 he received the Global Hepatitis Award from the International Symposium on Viral Hepatitis and Liver Disease (ISVHLD). He serves as a Senior Advisor for the International Coalition to Eliminate HBV (ICE-HBV). He is also a Fellow of the American Society of Microbiology. In September 2018, Dr. Schinazi received France’s highest civilian honor, Chevalier de la Légions D’honneur for saving millions of lives globally. He was elected to the American Association of the Advancement of Science in December 2020. He was elected to the Section on Pharmaceutical Sciences for his “distinguished contributions to the field of pharmacology and medicinal chemistry, particularly for antiviral therapies”. Dr. Schinazi served as Trustee on the amfAR Board of Directors. He is internationally recognized as one of the most influential persons in the life science sector. His research currently focuses on identifying agents that could be used to eliminate HIV, hepatitis B, SARS-CoV-2, yellow fever, and other emerging infections.

BIOGRAPHIES



Serena Spudich
Yale University, USA

Serena is Gilbert H. Glaser Professor of Neurology, Chief, Division of Neurological Infections and Global Neurology, and Co-Director, Center for Brain and Mind Health at Yale University. Her clinical and translational research explores effects of HIV and SARS-CoV-2 infection in the nervous system, focusing on effects of acute infection, antiviral and immune treatments, and interventional strategies on viral pathogenesis and persistence in the central nervous system. She collaborates with investigators from multiple disciplines in studies in the United States and in international settings, especially in Bangkok, Thailand, exploring questions of inflammation, injury, and viral reservoirs within the central nervous system. She has been active in the International AIDS Clinical Trials Group, co-leads the International NeuroHIV Cure Consortium, serves on the US DHHS Antiretroviral Treatment Guidelines Committee, CROI Program Committee, and currently serves as the Steering Committee Co-Chair for the NIH RECOVER study on long COVID. She also is a neurology physician who cares for patients with viral infections and neurological disorders in clinics at Yale.



Mario Stevenson
University of Miami, USA

Dr. Mario Stevenson is the Raymond F. Schinazi and Family Endowed Chair in Biomedicine, Director of the University of Miami AIDS Institute and Co-Director of the Center for AIDS Research at the University of Miami Miller School of Medicine. Prior to 2011, Dr. Stevenson was the David Freeland Chair for AIDS Research at the University of Massachusetts Medical School and the Director of the Center for AIDS research at that Institution. Dr. Stevenson obtained his BSc. (1980) and PhD (1984) in Glasgow, Scotland.

Dr. Stevenson is a molecular virologist who has been working on the viral etiology of AIDS for over 30 years. Dr. Stevenson's has been investigating mechanisms regulating HIV replication, persistence and disease pathogenesis. Dr. Stevenson has served as Chair of the HIV AIDS Virology Study Section at the National Institutes of Health, Chair of the Scientific Advisory Board of the National AIDS Conference (CROI), and has served on the NIH Office of AIDS Research that sets AIDS research directives. From 2006-2015, he served as Chair of the Scientific Advisory Board and is currently a member of the Board of Trustees of the American Foundation for AIDS Research (amfAR) and a scientific board member of the Elizabeth Glaser Pediatric AIDS Foundation. Dr. Stevenson is a recipient of Harvard Medical School's Shipley Lectureship, recipient of the Gertrude Elion award, Schally Research Award and Barcelona's IRSI-Caixa award.

BIOGRAPHIES



Rabindra Tirouvanziam

Emory University, USA

Rabindra Tirouvanziam earned his Bioengineering degree at Agro Paris Tech (France) and his PhD in developmental biology, lung physiology and immunology at the College de France and National Centre for Scientific Research (Paris, France). He trained as a postdoctoral researcher in genetics at Stanford University (CA, USA) before joining Emory University as faculty. Research in his group include patient- and model-based studies in cystic fibrosis, flu, COVID-19, TB, and malaria, focusing on immunology and metabolism. The Tirouvanziam lab emphasizes sample collection from patients and optimized in vitro and animal models combined with high-content analyses by cytometry and transcriptomics (for cells) and multiplexed ELISA and mass spectrometry (for fluids) to delineate mechanisms of immunometabolism and their relations to chronic disease. The Tirouvanziam lab has received support from NIH, NSF, DARPA, and the CF Foundation. As of October 2022, Dr. Tirouvanziam counts over 80 papers, 150 abstracts and 5 patents. More information at: <https://tirouvanziam-lab.com>.



Susan Weiss

University of Pennsylvania, USA

Susan Weiss obtained her PhD in Microbiology from Harvard University working on paramyxoviruses and did postdoctoral training in retroviruses at University of California, San Francisco. She came to the University of Pennsylvania (Penn) as an Assistant Professor in 1980, and is currently Professor and Vice Chair, Department of Microbiology and Co-director of the Penn Center for Research on Coronaviruses and Other Emerging Pathogens at the Perelman School of Medicine at Penn. She previously served as Associate Dean for Biomedical Postdoc Programs (2010-2019). She has worked on many aspects of coronavirus replication and pathogenesis over the last forty years, making contributions to understanding the basic biology as well as viral entry, organ tropism and virulence. This work focused for many years on the murine coronavirus (MHV) mouse model of hepatitis. More recently she has work on SARS-CoV and MERS-CoV and since 2020 also on SARS-CoV-2, as well as the “common” coronaviruses. Her work for the last ten years has focused on coronavirus interaction with the host innate immune response, viral antagonists of double-stranded RNA induced antiviral pathways and interactions with the unfolded protein responses. Most recent work also focusses on coronavirus infection of the nasal epithelium, the earliest site of infection. Her other research interests include activation and antagonism of the double-stranded RNA induced antiviral responses, with a focus on the oligoadenylate-ribonuclease L (OAS-RNase L) pathway, flavivirus-primarily Zika-virus-host interactions and pathogenic effects of host endogenous dsRNA.

BIOGRAPHIES



Wendy Yeh

Vir Biotechnology, USA

Dr. Yeh is an experienced physician-scientist and drug developer who has been responsible for the successful clinical development and registration of multiple transformative medicines. She brings 20+ years of experience in research and clinical development in infectious diseases and immunology, and currently oversees the clinical development pipeline for the Respiratory portfolio at Vir. Prior to Vir, she held multiple positions of increasing responsibility at Merck Research Laboratories and Principia Biopharma. She has been responsible for the successful clinical development, registration, and lifecycle management of multiple transformative medicines, such as grazoprevir/elbasvir (Zepatier®) for treatment of HCV, letermovir (Prevymis™) for prevention of CMV in immunocompromised hosts, and sotrovimab (Xevudy) for treatment of SARS-CoV2.

Dr. Yeh earned her B.S. from Stanford University, M.D. from University of Washington, and completed her clinical training in Internal Medicine and Infectious Diseases at Brigham and Women's Hospital and Massachusetts General Hospital in Boston. Prior to joining industry, Wendy held the position of Assistant Professor in Medicine at Harvard Medical School.

DISCLOSURE STATEMENT



DISCLOSURE STATEMENT

It is the intent of Emory University School of Medicine to assure that its education mission, and continuing medical education activities in particular, not be influenced by the special interest of individuals associated with its programs. All faculty participating in a sponsored activity are expected to disclose to the audience two important points:

1. any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation;
2. any significant financial interest with any commercial supporters of the activity. (Significant financial interest or other relationships can include such things as grants or research support, employee, consultant, major stockholder, member of speakers bureau, etc.).

All disclosed financial relationships were reviewed for potential conflicts of interest. Actions were taken to resolve any identified conflicts.

REPORTING FORM

(Promotion of Commercial Product, Technology, Program and/or Service)

Emory University School of Medicine is committed to providing continuing medical education activities that are scientifically rigorous, clinically balanced, evidence-based and free of commercial bias and promotion.

Instructions:

1. Use this form to document any concerns about commercial promotion in presentations and/or materials.
2. Please provide the following details:

Date:	Promotion of: (check all applicable)	Promotion by: (Faculty's name)	Promotion via: (i.e. slides, handouts)
_____	{ } Product:	_____	_____
	{ } Technology:	_____	_____
	{ } Service:	_____	_____
	{ } Other:	_____	_____

Specific details: _____

Please note that your completed form will be shared with the activity's planning committee and your concerns will be addressed appropriately.

REPORTING FORM

(Promotion of Commercial Product, Technology, Program and/or Service)

Emory University School of Medicine is committed to providing continuing medical education activities that are scientifically rigorous, clinically balanced, evidence-based and free of commercial bias and promotion.

Instructions:

1. Use this form to document any concerns about commercial promotion in presentations and/or materials.
2. Please provide the following details:

Date:	Promotion of: (check all applicable)	Promotion by: (Faculty's name)	Promotion via: (i.e. slides, handouts)
_____	{ } Product:	_____	_____
	{ } Technology:	_____	_____
	{ } Service:	_____	_____
	{ } Other:	_____	_____

Specific details: _____

Please note that your completed form will be shared with the activity's planning committee and your concerns will be addressed appropriately.

POLICY INFORMATION

Funding for DART 2022 is in-part provided by the NIH. As a partner with the NIH, DART 2022 is committed providing a safe environment free of sexual, racial, and ethnic harassment and discrimination.

Harassment includes verbal, written or physical conduct that denigrates or shows hostility toward an individual based on race, color, religion, sex (including pregnancy), sexual orientation, gender identity or expression, national origin, age, disability, marital status, citizenship, genetic information, or any other characteristic protected by law. Harassment is defined as behavior that is severe to pervasive enough to create an environment that a reasonable person would consider to be intimidating, hostile, offensive or abusive. Examples include but are not limited to commenting on or making fun of a person's religious beliefs, using racially biased epithets, stalking or deliberate intimidation.

Sexual harassment is unwelcome sexual advances, requests for sexual favors, comments, gestures, or contact of a sexual nature whether on a one-time basis or in a continuous series of incidents that might reasonably be expected to offend or embarrass an individual. Some examples of sexual harassment include, but are not limited to offensive comments, inappropriate touching, engaging in derogatory stereotypes about members or a particular gender, telling obscene jokes, discussing sexual activities, the use of sexual language and imagery, accessing pornographic internet sites while at the Hilton meeting locations for DART 2022 (This includes all events and lectures at the conference; in-doors or outdoors), offering professional advantages, coercion, or attempted coercion in return for sexual favors.

Any person who believes that he or she is the victim of inappropriate conduct, including sexual or other forms of harassment or bullying, or that a colleague of DART 2022 affiliate has been subject to harassment, should promptly report the incident to DART 2022 staff at +1 404-551-4848 or DART 2022 staff on premises, identifiable by heather pink DART 2022 shirts and/or red lanyards.

All concerns will be treated seriously. DART 2022 will conduct a prompt and thorough investigation of all the circumstances surrounding the alleged incident and will keep the complaint and investigation confidential to the extent practicable. If the investigation leads DART 2022 to conclude that an individual has committed an act of harassment, that individual will be subject to appropriate actions, up to and including expulsion from the event premises and may no longer be allowed to participate in future DART events.

If you believe you have been in victim of harassment or bullying additional remedies include filing and complaint with [health and human services](#) (HHS) or filing a complaint with the [National Institutes of Health](#) (NIH). Seeking assistance from the conference organizer in no way prohibits filing a complaint with HHS or the NIH.

This policy information will be able to be referenced at <https://informedhorizonseducation.com/nih-safety> as well as the conference app.

Please reach out to the conference secretariat, Informed Horizons Education, at info@ihorizonsed.com if you have any questions or concerns about the DART 2022 policies.

ACKNOWLEDGEMENTS

GOLD



SILVER



GILEAD


BRONZE



CONTRIBUTORS



PARTNERS




SAVE THE DATE

MARK YOUR CALENDAR FOR 2023 & 2024

FRONTIERS IN DRUG DEVELOPMENT FOR HEPATOLOGY

HEP DART 2023

HACIENDA DEL MAR, LOS CABOS • 3-7 DECEMBER 2023



HIV DART & Respi DART 2024



Details TBA



www.informedhorizonseducation.com